MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù),。

Polyinosinic-polycytidylic acid

MCE 國(guó)際站：Polyinosinic-polycytidylic acid

品牌：MedChemExpress (MCE)

CAS：24939-03-5

貨號(hào)：HY-107202

Synonyms：Poly(I:C

存儲(chǔ)條件：粉末 -20°C 3 年 溶劑中 -80°C 6 個(gè)月 -20°C 1 個(gè)月

運(yùn)輸條件：美國(guó)大陸的室溫,；其他地方可能有所不同。

產(chǎn)品活性：Polyinosinic-polycytidylic acid (Poly(I:C)) 是雙鏈 RNA 的合成類似物,，是一種 TLR3 和視黃酸誘導(dǎo)型基因 I 受體 (RIG-I 和 MDA5) 的激動(dòng)劑,。Polyinosinic-polycytidylic acid 可以用作疫苗佐劑,，以增強(qiáng)先天性和適應(yīng)性免疫反應(yīng),，并改變腫瘤的微環(huán)境，還可以直接觸發(fā)癌細(xì)胞發(fā)生凋亡 (apoptosis),。

體外：Polyinosinic-polycytidylic acid (0.5-5 μg/mL, 3-24 h) 呈現(xiàn)劑量和時(shí)間依賴性增加誘導(dǎo)永生化氣道上皮細(xì)胞的細(xì)胞旁通透性[4],。 Polyinosinic-polycytidylic acid (5 μg/mL, 24 h) 對(duì) 16HBE14o- 細(xì)胞沒(méi)有細(xì)胞毒性[4]。 Polyinosinic-polycytidylic acid (5 μg/mL, 6 h) 在 16HBE14o- 細(xì)胞中誘導(dǎo)上皮頂端連接復(fù)合體和緊密連接的破壞[4],。 MCE尚未獨(dú)立證實(shí)這些方法的準(zhǔn)確性,。僅供參考。

體內(nèi)：Polyinosinic-polycytidylic acid (2.5-10 mg/mL, Stereotaxic injection, single dose) 在腦黑質(zhì)和背外側(cè)紋狀體中誘導(dǎo)持續(xù)的炎癥反應(yīng)[2],。 Polyinosinic-polycytidylic acid (10 μg/mouse, Intraperitoneal injection, single dose) 降低小鼠的肺腫瘤生長(zhǎng)[3],。 Polyinosinic-polycytidylic acid (1.25 mg/kg, Intraperitoneal injection, single dose) 在 MCAO 模型小鼠中通過(guò) TLR3 下調(diào)TLR4/MyD88 信號(hào)通路發(fā)揮腦缺血再灌注損傷的治療作用[5]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IC50 & Target：Bcl-2 Bax IL-17A IL-13 HSP70

銷售產(chǎn)品：Exatecan (mesylate)  | MRTX1133  | Cetuximab  | MG-132  | SBE-β-CD  | Rapamycin  | Tamoxifen  | Olaparib  | Sotorasib  | Eribulin (mesylate)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

參考文獻(xiàn)：

[1]. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732-738. [2]. Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun. 2002;293(5):1364-1369. [3]. Cheng Y, Xu F. Anticancer function of polyinosinic-polycytidylic acid [J]. Cancer biology & therapy, 2010, 10(12): 1219-1223.[4]. Deleidi M, Hallett P J, Koprich J B, et al. The Toll-like receptor-3 agonist polyinosinic: polycytidylic acid triggers nigrostriatal dopaminergic degeneration [J]. Journal of Neuroscience, 2010, 30(48): 16091-16101.[5]. Forte G, Rega A, Morello S, et al. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer [J]. The Journal of Immunology, 2012, 188(11): 5357-5364.[6]. Rezaee F, Meednu N, Emo J A, et al. Polyinosinic: polycytidylic acid induces protein kinase D–dependent disassembly of apical junctions and barrier dysfunction in airway epithelial cells [J]. Journal of Allergy and Clinical Immunology, 2011, 128(6): 1216-1224. e11.[7]. Wang P F, Fang H, Chen J, et al. Polyinosinic-polycytidylic acid has therapeutic effects against cerebral ischemia/reperfusion injury through the downregulation of TLR4 signaling via TLR3 [J]. The Journal of Immunology, 2014, 192(10): 4783-4794.